Oppenheimer has published a research report on Medtronic MDT lowering the price target.
In the report, Oppenheimer wrote, "On MDT's F1Q call, mgmt noted continued ICD/Spine pressures, reiterated FY12 guidance on solid performance from its remaining business lines/cost savings, and
discussed new CEO Omar Ishrak's priorities for reinvigorating growth."
Oppenheimer rated Medtronic an Outperform with a price target lowered from $48.00 to $42.00. Medtronic closed Tuesday at $33.10.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in